Daclatasvir + asunaprevir: first global approval

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis C virus (HCV) infection remains a significant global health concern.
• Current treatments often involve interferon and ribavirin, which have limitations and side effects.
• Direct-acting antiviral (DAA) agents represent a promising new class of HCV therapeutics.

Purpose of the Study:

• To summarize the development milestones of the daclatasvir + asunaprevir regimen.
• To highlight the first global approval of this combination therapy for HCV genotype 1 infections.
• To introduce an all-oral, interferon- and ribavirin-free treatment option.

Main Methods:

• Review of clinical development data for daclatasvir and asunaprevir.
• Analysis of regulatory submission and approval processes.
• Summary of preclinical and clinical trial outcomes (details not provided in abstract).

Main Results:

• Daclatasvir + asunaprevir, developed by Bristol-Myers Squibb, is approved in Japan.
• This regimen is indicated for chronic HCV genotype 1 infections, including compensated cirrhosis.
• It is the first all-oral, interferon- and ribavirin-free treatment for this indication.

Conclusions:

• The development of daclatasvir + asunaprevir marks a significant advancement in HCV treatment.
• This regimen offers a more convenient and potentially better-tolerated option for patients.
• The approval in Japan signifies a major milestone in combating chronic HCV genotype 1 infections.